CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data

Phase 2MixedNegative
AI Analysis

Summary

MapLight Therapeutics' stock declined 50% following the release of mixed Phase 2 data for a schizophrenia treatment candidate.

Clinical Trial Data

Phase

2

Importance:6/10
Sentiment:
-0.80
Phase 2 trialschizophreniamixed datastock decline

Read the original article

Published by Seeking Alpha Healthcare on July 27, 2026 11:49 AM

Read Original